Lord’s Mark Industries plans to start international clinical trials for its AI-driven, radiation-free breast cancer screening device in January 2027. With a commercial launch targeted for April 2027, the company is seeking to expand this technology into underserved global markets. Success hinges on meeting strict regulatory and clinical benchmarks in the US, UK, and Europe.
Lord’s Mark Industries has outlined a timeline to take its proprietary, AI-based breast cancer screening technology to international markets. After conducting initial trials in India, the company plans to launch Phase 2 clinical trials in the United States, Great Britain, and Europe by January 2027. The company aims to achieve a commercial rollout by April 2027, provided the technology passes clinical verification standards.
Technology and Development Context
The device, developed in partnership with the Centre for Materials for Electronic Technology (C-MET), uses thermal-sensor technology combined with AI for early detection of cellular abnormalities. The primary advantage proposed by the company is that the diagnostic tool is non-invasive and does not use radiation. This differentiates it from conventional mammography, which is the current standard for breast cancer screening. By offering a portable, radiation-free alternative, the company aims to improve access to early detection in infrastructure-limited areas and rural settings where traditional diagnostic equipment may be unavailable or difficult to maintain.
Regulatory and Market Strategy
Moving a medical device from the prototype phase to global markets involves navigating complex regulatory environments. In addition to the upcoming international trials, the company is concurrently working through the approval process with the Central Drugs Standard Control Organisation (CDSCO) in India. A major component of the firm's strategy involves policy advocacy. The company is in discussions with the Insurance Regulatory and Development Authority of India (IRDAI) to include this screening service under standard health insurance coverage. This, if achieved, would be a significant factor in making the technology affordable and widely available for patients.
Risks and Implementation Challenges
While the company targets a 98% detection accuracy, the real-world performance of such technology will be subject to rigorous scrutiny during international trials. Regulatory bodies in the US, UK, and Europe maintain high bars for safety and diagnostic accuracy, meaning clinical outcomes from these trials are critical. Furthermore, the healthcare sector is competitive, and the adoption of new screening tools often depends on acceptance by medical professionals and integration into established hospital workflows. The company will also need to demonstrate that its distribution and support infrastructure can handle a rollout across different regulatory jurisdictions. Investors and stakeholders should track the start of the January 2027 trials and any updates regarding clinical trial data and regulatory clearances, as these will be the primary determinants of the product's viability for the proposed commercial launch.